Supreme Court Reinforces Inducement Pleading Standard, Reversing Federal Circuit in “Skinny Label” Case

The Supreme Court today issued its decision in Hikma v. Amarin (Case No. 24-889). In a 9-0 opinion authored by Justice Ketanji Brown Jackson, the Court reversed the Federal Circuit, holding that it is not enough to plausibly allege that a generic pharmaceutical manufacturer’s “skinny label”[1] and related statements could be read as encouraging infringing use. Rather, a complaint must plausibly allege “clear” and “affirmative” acts of encouragement—not merely lawful, ambiguous, or speculative conduct.

In short, to plead that a defendant took “active steps . . . to encourage direct infringement,” as required to state a claim for inducement under both patent and copyright law, a plaintiff must allege more than vague statements combined with the possibility that others might interpret those statements as instructions to infringe.

As we anticipated in our May 1, 2026 Step Into IP Blog post, following oral argument, the decision largely turned on the familiar pleading standard established under Twombly and Iqbal. The Court rejected Amarin’s theory as “merely consistent with” liability, without allegations nudging the claim from “conceivable to plausible.”

Specifically, the Court rejected the notion that a defendant’s active inducement could be reasonably inferred from speculation about how others might interpret the defendant’s conduct. That inference is insufficient even though generic manufacturers “surely know (and perhaps even expect), that their products will be put to infringing use” in part due to state laws requiring substitution of lower cost generic drugs.[2] The Court thus rejected a perceived “trend” at the Federal Circuit allowing inducement to be inferred based on how “others may understand” a defendant’s statements, rather than on active encouragement by the defendant.[3]

The Court made clear, however, that Hikma went too far in suggesting that active inducement must be “express.” Rather, active inducement could also be shown through “implicit” encouragement, such as a suggestive product name or targeted advertising, provided the inducement is both “clear” to the directly infringing audience and “affirmative,” rather than passive.[4]

Manufacturers should therefore remain cautious about making statements that effectively promote infringing uses (whether patent, copyright, or otherwise) of their products, even if by implication. Intellectual property rightsholders, for their part, should consider whether they can support inducement theories with allegations of affirmative, albeit implicit, conduct designed to encourage infringement.

Justice Jackson, the author of this opinion, previously joined the unanimous opinion in Twitter v. Taamneh,[5] which rejected aiding-and-abetting liability for virtual platforms that hosted content used to recruit terrorists and raise funds for terrorism. Justice Jackson also wrote a short concurrence in Twitter to emphasize that the case, also arising at the pleading stage like Hikma, turned on the “particular allegations in [the] complaints” at issue. This case may similarly turn on what Amarin can plead going forward. At oral argument,[6] Amarin previewed that it may seek leave to amend the complaint based on additional facts, including those learned in discovery, which proceeded after the Federal Circuit’s now-reversed decision. The Supreme Court reiterated, however, that plausibility is a threshold to be met “[i]n order to proceed to discovery.” It will be interesting to see how Amarin frames any request for leave to amend.

More broadly, Hikma marks the third recent unanimous decision—alongside Twitter and Cox v. Sony—emphasizing that mere knowledge that others may (or will) commit a tort is not enough; inducement requires purposeful, affirmative encouragement of the violation.

Going forward, these decisions place a premium on pre-suit development of inducement claims. The Supreme Court made clear that liability requires clear and affirmative steps to encourage infringement—not merely statements that could be misused or conduct consistent with ordinary commercialization. Companies should therefore be mindful, before litigation, of how their labeling, marketing, and product positioning could be viewed as purposeful encouragement. Rightsholders, in turn, should consider whether both their allegations and their claim language support identifying concrete, targeted acts of inducement. In that sense, claim drafting and litigation strategy will be critical to developing inducement theories that can survive early dismissal.

[1] This is an FDA-approved drug label that “carves out” (omits) uses of the drug that are still protected by patents, so the generic can be sold legally for unpatented indications.

[2] The first two elements of inducement, direct infringement and specific intent, were presumed met. The only question was whether the element of active encouragement was met.

[3] The case it cites as evidence of that trend, GlaxoSmithKline v. Teva, was a prior iteration of the “skinny labels” dispute.

[4] Quoting Grokster, a 2005 copyright decision, involving a suggestive name and targeted advertising.

[5] Cited in Hikma at Slip Op. at 11–12.

[6] At 58–62.